Despite what it sees as improvements across multiple regulatory fronts over the past few years, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) says “there still exists room for improvement” to increase the number of new drug approvals it issues ahead of any other country.
In a new activity update, chief executive Yasuhiro Fujiwara points out that the number of such clearances has already been...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?